Who Paid My Doc
Dirk Davidson
Crossville, TN Medical Doctor
NPI 1659369429 CMS profile 211558
49 Cleveland St, Suite 270, Crossville, TN 38555
General payments
$21,277
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Dirk Davidson of Crossville, TN is reported in the CMS Open Payments database as having received $21,277 across 1,126 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,829 | 171 | |
| 2024 | General | $3,528 | 170 | |
| 2023 | General | $3,513 | 174 | |
| 2022 | General | $3,068 | 161 | |
| 2021 | General | $2,923 | 166 | |
| 2020 | General | $2,114 | 131 | |
| 2019 | General | $2,303 | 153 |
Beside peers
- Dirk Davidson
- Tennessee median
- Middle half of Tennessee
- National median
In program year 2025, general payments to Dirk Davidson were reported at $3,829. Among 24,836 Tennessee profiles paid that year, the median was $199 and the middle half received between $54 and $728.
Show as a table
| Year | Dirk Davidson | Tennessee median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,303 | $197 | $58–$789 | $163 |
| 2020 | $2,114 | $132 | $38–$484 | $114 |
| 2021 | $2,923 | $145 | $39–$541 | $132 |
| 2022 | $3,068 | $170 | $50–$642 | $149 |
| 2023 | $3,513 | $183 | $50–$668 | $160 |
| 2024 | $3,528 | $187 | $51–$700 | $164 |
| 2025 | $3,829 | $199 | $54–$728 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 84 drugsPart D claims
4,054
Drug cost
$12,997,671
Branded share of claims
46.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | Brand | 133 | $1,866,144 | |
| Lupron Depot Leuprolide Acetate | Brand | 171 | $994,322 | |
| Neulasta Onpro Pegfilgrastim | Brand | 75 | $621,995 | |
| Imbruvica Ibrutinib | Brand | 38 | $607,939 | |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | Brand | 38 | $554,306 | |
| Ibrance Palbociclib | Brand | 33 | $523,673 | |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 77 | $514,225 | |
| Lenalidomide | Generic | 45 | $484,883 | |
| Keytruda Pembrolizumab | Brand | 33 | $468,790 | |
| Revlimid Lenalidomide | Brand | 32 | $452,561 |
The 10 drugs with the highest cost, of 84 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 130 billing codesPaid by Medicare
$5,049,500
Medicare patients
959
Services billed
249,293
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Cancer | 46% | |
| Ischemic heart disease | 33% | |
| Diabetes | 32% | |
| Osteoporosis | 30% | |
| Chronic kidney disease | 25% | |
| COPD | 25% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 29 | 29,800 | $1,311,698 |
| Injection, denosumab, 1 mg J0897 | Office | 143 | 23,100 | $471,392 |
| Injection, eflapegrastim-xnst, 0.1 mg J1449 | Office | 25 | 12,408 | $252,344 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 71 | 10,700 | $166,856 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 | Office | 11 | 2,896 | $104,683 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 | Office | 17 | 4,960 | $30,735 |
| Injection, triptorelin pamoate, 3.75 mg J3315 | Office | 11 | 78 | $26,977 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 15 | 1,190 | $4,145 |
| Vaccine for influenza for injection into muscle 90662 | Office | 43 | 43 | $3,436 |
| Injection, fluorouracil, 500 mg J9190 | Office | 17 | 938 | $2,089 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 83 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ENHERTU |
|
$163 | — | — |
| KEYTRUDA |
|
$152 | 33 | — |
| KISQALI |
|
$135 | — | — |
| FOTIVDA |
|
$131 | — | — |
| REBLOZYL |
|
$108 | 22 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 83 with PatronRecords
1,126 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.